{"id":374490,"date":"2026-04-11T12:04:39","date_gmt":"2026-04-11T12:04:39","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/374490\/"},"modified":"2026-04-11T12:04:39","modified_gmt":"2026-04-11T12:04:39","slug":"wegovy-hd-7-2mg-now-available-for-chronic-weight-management","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/374490\/","title":{"rendered":"Wegovy HD 7.2mg Now Available for Chronic Weight Management"},"content":{"rendered":"<p>Wegovy\u00ae HD (semaglutide) injection 7.2mg is now available for adult patients for whom additional weight reduction is clinically indicated after tolerating the 2.4mg dosage for at least 4 weeks.<\/p>\n<p>The new dose was approved based on data from the phase 3b STEP UP trial (ClinicalTrials.gov Identifier: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05646706#xd_co_f=ZTY1ZjA2MjAtMjJiZC00NTY3LWE4N2EtMTQzMjg5YmY3ZWUw~\" rel=\"nofollow noopener\" target=\"_blank\">NCT05646706<\/a>), which enrolled patients with a body mass index of at least 30kg\/m2 and without diabetes. Study participants were randomly assigned to receive subcutaneous semaglutide 7.2mg, semaglutide 2.4mg, or placebo once weekly, alongside lifestyle interventions.<\/p>\n<p>Findings showed treatment with semaglutide 7.2mg was associated with an average weight loss of 21%, if all patients stayed on treatment (efficacy estimand), compared with 18% with semaglutide 2.4mg and 2% with placebo. Similarly, weight reductions of approximately 19%, 16%, and 4% were observed with semaglutide 7.2mg, 2.4mg, and placebo, respectively, regardless of whether patients stayed on treatment (treatment regimen estimand).<\/p>\n<p>The most common adverse reactions reported with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and flatulence. Additionally, 22% of patients treated with the 7.2mg dosage experienced altered skin sensation (ie, sensitive skin, hyperesthesia, dysesthesia, paresthesia) compared with 6% in the semaglutide 2.4mg group and 0% in the placebo group.<\/p>\n<p>Wegovy HD is supplied in a prefilled, disposable, single-dose pen injector containing 7.2mg\/0.75mL of semaglutide. Each carton contains 4 pen injectors. The price of Wegovy HD for patients who opt to self-pay is $399 per month. The product is available nationwide at retail pharmacies, select telehealth providers and through <a href=\"https:\/\/www.novocare.com\/pharmacy.html\" rel=\"nofollow noopener\" target=\"_blank\">NovoCare\u00ae Pharmacy<\/a>.<\/p>\n<p>\u201cWe know that patients are looking for additional options for weight loss, and with Wegovy HD we are answering that call,\u201d said Ed Cinca, senior vice president, Marketing &amp; Patient Solutions at Novo Nordisk. \u201cWhether patients haven\u2019t yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what\u2019s possible with this new dose, and that\u2019s an opportunity we\u2019re excited to provide.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Wegovy\u00ae HD (semaglutide) injection 7.2mg is now available for adult patients for whom additional weight reduction is clinically&hellip;\n","protected":false},"author":2,"featured_media":374491,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[134,524,1927,195400,111,139,69,4368],"class_list":{"0":"post-374490","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-metabolic-disorders","11":"tag-mpr-newsletter-top-trend","12":"tag-new-zealand","13":"tag-newzealand","14":"tag-nz","15":"tag-obesity"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/374490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=374490"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/374490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/374491"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=374490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=374490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=374490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}